The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.e

Organizing pneumonia pattern (an area or areas of consolidation on imaging)

Publications

Martins RS, Machado JA, Teixeira R

Secondary bronchiolitis obliterans organizing pneumonia during treatment of chronic hepatitis C: role of pegylated interferon alfa-2a.

Revista da Sociedade Brasileira de Medicina Tropical 2012 Oct;45;655-6 — 2012 Oct — 655-6

Kang EJ, Kim DK, Jeon SR, Choi HS, Jeong SW, Jang JY, Lee JS, Uh ST

Interstitial pneumonitis in a patient with chronic hepatitis C and chronic renal failure on interferon therapy.

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2011 Jul;58;47-52 — 2011 Jul — 47-52

Slavenburg S, Heijdra YF, Drenth JP

Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Digestive diseases and sciences 2010 Mar;55;579-85 — 2010 Mar — 579-85

Oymak FS, Demirba? HM, Mavili E, Akgun H, Gulmez I, Demir R, Ozesmi M

Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases.

Respiration; international review of thoracic diseases 2005 May-Jun;72;254-62 — 2005 May-Jun — 254-62

Kalambokis G, Stefanou D, Arkoumani E, Kitsanou M, Bourantas K, V Tsianos E

Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia.

European journal of haematology 2004 Jul;73;67-70 — 2004 Jul — 67-70

Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.

The American journal of gastroenterology 2002 Sep;97;2432-40 — 2002 Sep — 2432-40

Ogata K, Koga T, Yagawa K

Interferon-related bronchiolitis obliterans organizing pneumonia.

Chest 1994 Aug;106;612-3 — 1994 Aug — 612-3